Related Experiment Videos
Methotrexate osteopathy demonstrated by Technetium-99m HDP bone scintigraphy
H Stevens1, J W Jacobs, P P Van Rijk
1Department of Nuclear Medicine, University Medical Center, Heidelberglaan 100, 3508 GA Utrecht, The Netherlands. stevens.henk@wxs.nl
Clinical Nuclear Medicine
|April 24, 2001
Summary
Methotrexate osteopathy, a bone condition from methotrexate use in rheumatoid arthritis, can be detected by Tc-99m HDP bone scans. These scans are sensitive to metabolic bone changes, aiding diagnosis.
Area of Science:
- Rheumatology
- Nuclear Medicine
- Radiology
Background:
- Methotrexate is a common drug for rheumatoid arthritis and other inflammatory conditions.
- Methotrexate can cause methotrexate osteopathy, a bone metabolism disorder.
- Osteoporosis and microfractures are key features of methotrexate osteopathy.
Observation:
- A case study involving a rheumatoid arthritis patient with methotrexate osteopathy is presented.
- Radiographic imaging struggles to visualize microfractures associated with the condition.
- Technetium-99m HDP bone scintigraphy was utilized for diagnosis.
Findings:
- Tc-99m HDP bone scintigraphy effectively revealed methotrexate osteopathy.
- The bone scan demonstrated characteristic changes in bone metabolism.
- This imaging technique proved sensitive to the effects of methotrexate on bone.
Implications:
- Tc-99m HDP bone scintigraphy is a valuable tool for diagnosing methotrexate osteopathy.
- Early detection can help manage bone complications in patients on methotrexate.
- This highlights the importance of monitoring bone health in patients receiving methotrexate therapy.